Eikon Therapeutics Closes $148 Million Series A Financing To Develop High-Throughput, Super-Resolution Microscopy For Drug Discovery

May 05, 2021•about 4 years ago

Amount Raised

$148 Million

Round Type

series a

HaywardHealth Care

Description

Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. The company also announced the appointment of Roger M. Perlmutter, MD, PhD, as its new Chief Executive Officer.

Company Information

Company

Eikon Therapeutics

Location

Hayward, California, United States

About

Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and automation with the goal of bringing important new medicines to patients suffering from grievous illness. Scientists at Eikon measure the real-time movement of individual proteins in living cells to develop differentiated therapeutics. Eikon is based in Hayward, California and can be found online via our website or on Twitter or LinkedIn.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Eikon Therapeutics Closes $148 Million Series A Financing To Develop High-Throughput, Super-Resolution Microscopy For Drug Discovery

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information